𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost-effectiveness of various guidelines for adjuvant systemic therapy in primary breast cancer

✍ Scribed by M Bolster; W Kievit; G.J Van der Wilt; E Adang; P Bult; E Thunnissen; J Meijer; L Beex; V Tjan-Heijnen

Book ID
118622018
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
348 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness of switching to exeme
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

[Cancer Treatment and Research] Adjuvant
[Cancer Treatment and Research] Adjuvant Therapy for Breast Cancer Volume 151 || Costs of Adjuvant Breast Cancer Treatments
✍ Castiglione, Monica; Piccart, Martine J. πŸ“‚ Article πŸ“… 2009 πŸ› Springer US 🌐 English βš– 386 KB

Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction o